News

Patients with higher exercise capacity present a reduced risk of pulmonary arterial hypertension-associated death or hospitalization, according to results of a Phase 3 clinical trial. The research was published in the journal PLOS One, in a study titled “Association between six-minute walk distance and long-term outcomes in patients…

The University of Virginia’s (UVA) Pulmonary Hypertension Center has been recognized as a Center of Comprehensive Care by the Pulmonary Hypertension Association (PHA). The PHA-accredited PH Care Centers initiative aims to establish an accreditation program for centers with special expertise in pulmonary hypertension (PH), particularly pulmonary arterial hypertension…

A protein called KLF15 has an important protective role in the lung, according to the findings of Johns Hopkins researchers. KLF15 was found to be a critical regulator of genes that are necessary for the maintenance of proper lung blood vessels’ function. In addition, the protein was shown to…

People with systemic sclerosis (SSc) that have borderline high pulmonary arterial pressure are at increased risk of developing pulmonary hypertension (PH), and may benefit from regular examinations through right heart catheterization, a study found. Pulmonary hypertension often appears as a disease complication of systemic…

Poor renal function is linked to an increased prevalence of pulmonary hypertension (PH) in patients with chronic kidney disease (CKD), a retrospective study suggests. The study, “Epidemiology and risk factors in CKD patients with pulmonary hypertension: a retrospective study,” was published in the journal BMC…

Bardoxolone methyl, Reata Pharmaceuticals’ treatment candidate for pulmonary hypertension (PH), improves exercise capacity and has a safe profile in patients with PH associated with interstitial lung disease (ILD), according to top-line results from a Phase 2 clinical trial. ILD is a group of several lung…

American researchers have identified three blood-flow measurements that could help doctors predict the outcomes of people whose pulmonary hypertension stems from a serious heart condition. The discovery applies to PH patients whose lung blood pressure disorder is associated with heart failure with preserved ejection fraction, or PH-HFpEF. A diagnosis of…

Deficiency of an enzyme called granzyme B leads to deposits of calcium in pulmonary blood vessels, contributing to the defects found in hypoxic pulmonary arterial hypertension (PAH), an animal study suggests. The study, “Granzyme B deficiency promotes osteoblastic differentiation and calcification of vascular smooth muscle cells in…

Genetic sequencing and the speed with which it can help diagnose a child’s disease — in addition to revealing the genes that cause at least half of the 7,000 rare diseases currently known — was the focus of a discussion by three top New York geneticists. The Feb. 28 conference,…

Bellerophon Therapeutics is advancing the clinical trials program of its inhaled INOpulse nitric oxide therapy for pulmonary hypertension (PH) associated with several lung diseases. The company is developing INOpulse for patients with pulmonary arterial hypertension (PAH), PH associated with chronic obstructive pulmonary disease (COPD), and PH linked to interstitial lung…

Cardiome recently shared an update on the development of its therapeutic portfolio, including Trevyent (treprostinil injection) for the treatment of pulmonary arterial hypertension (PAH). Following the U.S. Food and Drug Administration’s (FDA) refusal last year to approve a new drug application (NDA) submitted by Trevyent’s licensor SteadyMed,…

When it comes to rare diseases, one that definitely makes the list is spinal muscular atrophy with respiratory distress — SMARD,  for short. Hunter Pageau, a 12-year-old boy from North Haven, Connecticut, is one of only 80 people in the world known to have SMARD, a motor neuron disease…